Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy
Copyright 2022, Business Wire.
news
2022-10-18 00:00:00

October 17, 2022 08:00 PM Eastern Daylight Time BEIJING, China & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Eucure (Beijing) Biopharma Co., Ltd. ('Eucure'), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen'), announced today that the company has entered into a worldwide licensing agreement with Syncromune, Inc. ('Syncromune'), a US-based clinical stage biopharmaceutical company, for the development and commercialization of intratumoral immunotherapies along with Syncromune's Syncrovaxâ„¢ technology.
